TABLE 1.
Characteristics of candidates for prevention and treatment of postpartum hemorrhage, ranked as high or medium potential
| Name | Product type | Archetype | R&D stage for PPH | Indication | Administration route | Drug subclass |
|---|---|---|---|---|---|---|
| High‐potential candidates | ||||||
| Oxytocin – heat stable and inhaled | Drug | New chemical or biological entity | Phase I | Prevention and treatment of PPH | Inhalation | Uterotonic |
| Medium‐potential candidates | ||||||
| Melatonin | Drug | Repurposed | Phase II | Prevention and treatment of PPH | Sublingual, oral | Antioxidant |
| Vasopressin | Drug | Repurposed | Phase II | Prevention and treatment of PPH | Intravenous, intramyometrial, subcutaneous | Vascular agent |
| Dofetilide (nanoparticle delivery) | Drug | New chemical or biological entity | Preclinical | Prevention and treatment of PPH | Oral | Antiarrhythmic |